{"id":"W4389519919","doi":"10.1038/s41591-023-02726-5","title":"Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); Saskatchewan Cancer Agency; McGill University; Jewish General Hospital","funders":"Genentech; F. Hoffmann-La Roche; Roche","keywords":"Refractory (planetary science); Internal medicine; Lymphoma; Medicine; Oncology; Aggressive lymphoma; Brentuximab vedotin; Cancer research; Biology; Hodgkin lymphoma; Rituximab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001878383,0.0007357103,0.001244662,0.0003178468,0.000261511,0.001015683,0.0005432312,0.0008032966,0.001587754],"category_scores_gemma":[0.0006684771,0.0002945735,0.0007384279,0.0002705001,0.000499665,0.0006482929,0.000306077,0.001961294,0.0003875515],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007670537,"about_ca_system_score_gemma":0.0008909807,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005280831,"about_ca_topic_score_gemma":0.00139721,"domain_scores_codex":[0.9994583,0.0002868734,0.00002951092,0.00008725962,0.00005675038,0.00008134018],"domain_scores_gemma":[0.99953,0.00007747877,0.00009939006,0.00003903081,0.00003131888,0.0002228531],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6208788,0.03602114,0.01003963,0.000879768,0.001413681,0.0004146573,0.0003683037,0.003032687,0.08495679,0.000447007,0.003883318,0.2376642],"study_design_scores_gemma":[0.6464801,0.3175025,0.01922148,0.00007364179,0.0006741238,0.0006112767,0.00006770737,0.002588377,0.007554492,0.0003081587,0.004885628,0.00003259627],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939819,0.00274714,0.000306739,0.0003744296,0.00005883522,0.0009350011,0.00030302,0.00007031648,0.001222627],"genre_scores_gemma":[0.9935016,0.001315443,0.001159989,0.0005896075,0.0001431974,0.001017447,0.0008923134,0.00001850736,0.001361883],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001878383,"threshold_uncertainty_score":0.009933949,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02209722025973871,"score_gpt":0.3634544553876059,"score_spread":0.3413572351278672,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}